Matthew K Ito

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. doi request reprint Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
    Matthew K Ito
    Oregon Health and Science University College of Pharmacy, Oregon State University, 2730 SW Moody Ave, CL5CP, Portland, OR, 97201 5042, USA
    Drugs 75:1715-24. 2015
  2. doi request reprint Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study
    Matthew K Ito
    Oregon State University Oregon Health and Science University College of Pharmacy, 3303 SW Bond Avenue, Portland, OR 97239, USA Electronic address
    J Clin Lipidol 8:69-76. 2014
  3. doi request reprint Dyslipidemia: management using optimal lipid-lowering therapy
    Matthew K Ito
    College of Pharmacy, Oregon State University Oregon Health and Science University, Portland, USA
    Ann Pharmacother 46:1368-81. 2012
  4. ncbi request reprint Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias--2005
    Matthew K Ito
    College of Pharmacy, Oregon State University, Portland Program at Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Pharmacotherapy 26:939-1010. 2006
  5. ncbi request reprint ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
    Matthew K Ito
    College of Pharmacy, Oregon State University Oregon Health and Science University, Portland Campus at OHSU, 3303 SW Bond Ave, Portland, OR 97239, USA
    Ann Pharmacother 41:1669-78. 2007
  6. doi request reprint What combination therapy with a statin, if any, would you recommend?
    Carlos A Dujovne
    Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Curr Atheroscler Rep 13:12-22. 2011
  7. ncbi request reprint Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction
    Matthew K Ito
    University of California, San Diego School of Medicine, La Jolla, California, USA
    Pharmacotherapy 26:85S-97S; discussion 98S-101S; quiz 106S-108S. 2006

Detail Information

Publications7

  1. doi request reprint Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
    Matthew K Ito
    Oregon Health and Science University College of Pharmacy, Oregon State University, 2730 SW Moody Ave, CL5CP, Portland, OR, 97201 5042, USA
    Drugs 75:1715-24. 2015
    ..The newly approved inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), evolocumab, also shows promise for the management of FH. Because of the extremely high risk for ASCVD, HoFH patients should be identified early. ..
  2. doi request reprint Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study
    Matthew K Ito
    Oregon State University Oregon Health and Science University College of Pharmacy, 3303 SW Bond Avenue, Portland, OR 97239, USA Electronic address
    J Clin Lipidol 8:69-76. 2014
    ..Drug interactions have been identified as a risk factor for muscle-related side effects in statin users...
  3. doi request reprint Dyslipidemia: management using optimal lipid-lowering therapy
    Matthew K Ito
    College of Pharmacy, Oregon State University Oregon Health and Science University, Portland, USA
    Ann Pharmacother 46:1368-81. 2012
    ..To evaluate current approaches and explore emerging research related to dyslipidemia management...
  4. ncbi request reprint Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias--2005
    Matthew K Ito
    College of Pharmacy, Oregon State University, Portland Program at Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Pharmacotherapy 26:939-1010. 2006
    ..Research articles were chosen based on the significance of findings, relevance to practice, quality of research, and timeliness; recent articles were given priority over earlier ones unless they demonstrated groundbreaking findings...
  5. ncbi request reprint ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
    Matthew K Ito
    College of Pharmacy, Oregon State University Oregon Health and Science University, Portland Campus at OHSU, 3303 SW Bond Ave, Portland, OR 97239, USA
    Ann Pharmacother 41:1669-78. 2007
    ....
  6. doi request reprint What combination therapy with a statin, if any, would you recommend?
    Carlos A Dujovne
    Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Curr Atheroscler Rep 13:12-22. 2011
    ....
  7. ncbi request reprint Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction
    Matthew K Ito
    University of California, San Diego School of Medicine, La Jolla, California, USA
    Pharmacotherapy 26:85S-97S; discussion 98S-101S; quiz 106S-108S. 2006
    ....